Global Secondary Progressive Multiple Sclerosis Drug Market Data Survey Report 2025

Table of Contents

1 Global Market Overview

• 1.1 Scope of Statistics
  • 1.1.1 Scope of Products
  • 1.1.2 Scope of Manufacturers
  • 1.1.3 Scope of Application
  • 1.1.5 Scope of Regions/Countries
• 1.2 Global Market Size

2 Regional Market

• 2.1 Regional Production
• 2.2 Regional Demand
• 2.3 Regional Trade

3 Key Manufacturers

• 3.1 AB Science SA
  • 3.1.2 Company Information
  • 3.1.2 Product Specifications
  • 3.1.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 3.2 Actelion Ltd
  • 3.2.1 Company Information
  • 3.2.2 Product Specifications
  • 3.2.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 3.3 Biogen, Inc.
  • 3.3.1 Company Information
  • 3.3.2 Product Specifications
  • 3.3.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 3.4 F. Hoffmann-La Roche Ltd.
  • 3.4.1 Company Information
  • 3.4.2 Product Specifications
  • 3.4.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 3.5 Genzyme Corporation
  • 3.5.1 Company Information
  • 3.5.2 Product Specifications
  • 3.5.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 3.6 Glialogix, Inc.
  • 3.6.1 Company Information
  • 3.6.2 Product Specifications
  • 3.6.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 3.7 Glialogix, Inc.
  • 3.7.1 Company Information
  • 3.7.2 Product Specifications
  • 3.7.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 3.8 Innate Immunotherapeutics Ltd
  • 3.8.1 Company Information
  • 3.8.2 Product Specifications
  • 3.8.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 3.9 Kyorin Pharmaceutical Co., Ltd.
  • 3.9.1 Company Information
  • 3.9.2 Product Specifications
  • 3.9.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 3.10 Mallinckrodt Plc
  • 3.10.1 Company Information
  • 3.10.2 Product Specifications
  • 3.10.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 3.11 MedDay SA
• 3.12 MedImmune, LLC
• 3.13 Merck KGaA
• 3.14 Meta-IQ ApS
• 3.15 Novartis AG
• 3.16 Opexa Therapeutics, Inc.
• 3.17 Xenetic Biosciences (UK) Limited

4 Major Application

• 4.1 Hospital
  • 4.1.1 Overview
  • 4.1.2 Hospital Market Size and Forecast
• 4.2 Clinic
  • 4.2.1 Overview
  • 4.2.2 Clinic Market Size and Forecast
• 4.3 Others
  • 4.3.1 Overview
  • 4.3.2 Others Market Size and Forecast

5 Market by Type

• 5.1 Inebilizumab
  • 5.1.1 Overview
  • 5.1.2 Inebilizumab Market Size and Forecast
• 5.2 GLX-1112
  • 5.2.1 Overview
  • 5.2.2 GLX-1112 Market Size and Forecast
• 5.3 DC-TAB
  • 5.3.1 Overview
  • 5.3.2 DC-TAB Market Size and Forecast
• 5.4 Etomoxir
  • 5.4.1 Overview
  • 5.4.2 Etomoxir Market Size and Forecast
• 5.5 IB-MS
  • 5.5.1 Overview
  • 5.5.2 IB-MS Market Size and Forecast
• 5.6 IB-MS
  • 5.6.1 Overview
  • 5.6.2 IB-MS Market Size and Forecast

6 Conclusion